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Transforming growth factor-β (TGF-β) is a highly pleio-
tropic cytokine playing pivotal roles in immune regulation. 
TGF-β facilitates tumor cell survival and metastasis by tar-
geting multiple cellular components. Focusing on its im-
munosuppressive functions, TGF-β antagonists have been 
employed for cancer treatment to enhance tumor immunity. 
TGF-β antagonists exert anti-tumor effects through #1 ac-
tivating effector cells such as NK cells and cytotoxic CD8
+ T 
cells (CTLs), #2 inhibiting regulatory/suppressor cell pop-
ulations, #3 making tumor cells visible to immune cells, #4 
inhibiting the production of tumor growth factors. This review 
focuses on the effect of TGF-β on T cells, which are differ-
entiated into effector T cells or newly identified tu-
mor-supporting T cells. 
[Immune Network 2009;9(4):122-126]
INTRODUCTION
Transforming growth factor-β (TGF-β) superfamily consists 
of a large family of structurally related cytokines, which are 
classified  into  two  main  groups:  TGF-β/Activin  and  bone 
morphogenetic  proteins  (BMPs)  and  growth/differentiation 
factors  (GDFs)  (1). 
  A m o n g  t h e m ,  T G F - β has been well characterized as a rep-
resentative potent immunosuppressive cytokine. TGF-β has 
been reported to inhibit immune system by modulating both 
effectors and suppressors. TGF-β directly inhibits innate im-
mune cells such as macrophages and NK cells and adoptive 
immune cells such as CD4
＋ helper T cells and CD8
＋ cyto-
toxic T cells, while expanding immunosuppressive regulatory 
T  cells  (Tregs)  and  inducing  the  recruitment  of  im-
munosuppressive  myeloid-derived  suppressor  cells  (2).
  T h e  i m m u n e  s u r v e i l l a n c e  s y s t e m  i s  o n e  o f  t h e  m o s t  i m-
portant  defense  mechanisms  against  cancer  progression. 
Attempts  to  enhance  tumor  immunity  by  various  strategies 
have been tried as supportive anti-cancer therapies. The most 
potent  immunosuppressive  cytokine,  TGF-β  is  massively 
produced  and  activated  in  tumor  microenvironment,  which 
a l l o w s  i n v a s i v e  m e t a s t a t i c  c a n c e r s  t o  e s c a p e  f r o m  i m m u n e  
surveillance (3). Thus, antagonizing TGF-β’s functions has 
been implicated as the most potent anti-tumor immune thera-
p y  a n d  s o m e  T G F - β antagonists  have  been  on  preclinical 
and  clinical  trials  (4-6).
PROGNOSIS AND THE SIZE/NUMBER OF 
METASTASIS
Tumor recurrence by remote metastasis affects the prognosis 
of cancer patients after radical surgery. Cancer staging is eval-
uated by TNM classification, which describes the size and the 
extent of the Tumor, degree of the spread to regional lymph 
Nodes and the presence of Metastasis. TNM staging is widely 
employed as a global standard to plan the treatments and to 
indicate the prognosis (7). Although there are no detailed pa-
rameters in metastasis defined in TNM staging, the size and 
the number of metastasis significantly affect the prognosis of 
the patients. In pulmonary metastasis from breast cancer, it 
has been reported that the size and the number of metastasis 
significantly  correlate  with  prognosis  and  re-recurrence  and 
the  pulmonary  metastasectomy  is  justified  in  case  of  small 
number of metastasis lesions (8). It has been reported that 
an increase in tumor size and an increase in number of re-Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
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Figure 1. TGF-β down-regulates the expression of NKG2D on CD8
+
T cells and NKG2D ligand on tumor cells.
gional lymph nodes with metastasis were associated with di-
minution in cellular immunity (9), which might be the con-
sequence of the production of TGF-β by tumors themselves 
and tumor infiltrating immunosuppressive cells (10,11). Thus, 
one might expect that the number and the size of tumor and 
metastasis could be reduced by blocking TGF-β to achieve 
better  prognosis. 
TGF-β AND TUMOR IMMUNE SURVEILANCE- 
AFFECTING NUMBER OF METASTASIS
Although some tumors express tumor specific antigens, which 
can be recognized by immune system, tumor specific immune 
responses often fail to eradicate tumors because tumors evade 
immune surveillance by variety of strategies. Tumors them-
selves,  tumor  stromal  cells  and  the  myeloid-derived  sup-
pressor cells produce large amount of TGF-β, which is acti-
vated in the tumor microenvironment (12-14). By its potent 
immunosuppressive effects, TGF-β strongly inhibits anti-tu-
mor  immunity.
  Partly due to TGF-β, loss or down-regulation of MHC class 
I molecules is frequently observed in malignant cells, which 
makes  them  invisible  to  immune  system  (15).  Poorly  im-
munogenic tumors with low expression of MHC class I can 
escape from attack by cytotoxic CD8
＋ T cells but they be-
come more sensitive to attack by NK cells (16). TGF-β also 
affects the tumor cell-NK cell interaction by modulating the 
expression of MHC class I homologues on the tumor cells and 
their receptors on NK cells. Expression of MHC class I homo-
logues  such  as  MHC  class-I-chain-related  protein  A  (MICA) 
and Rae-1γ human and murine NKG2D ligand, respectively, 
as  well  as  NKG2D  are  reported  to  be  down-regulated  by 
TGF-β (17-19) Nam JS et al. demonstrated that anti-TGF-β 
antibody treatment up-regulated NKG2D expression on CD8
＋ 
T  cells,  not  NK  cells,  which  were  already  highly  activated 
even without anti-TGF-β antibody treatment (19). Anti-TGF-
β antibody treatment exerts anti-tumor efficacy by enhancing 
tumor-immune  cell  interaction  (Fig.  1). 
  T G F - β directly  suppresses  functions,  migration  and  ex-
pansion of cytotoxic CD8
＋ T cells, NK cells, NK T cells and 
γ δ T cells, while inducing Foxp3
＋ Tregs (2). In poorly im-
munogenic syngeneic 4T1 mammary tumor metastasis model, 
TGF-β does not significantly affect the infiltration of NK cells 
and Foxp3
＋ Tregs, whereas depletion of CD8
＋ T cells abol-
ished the effect of anti-TGF-β antibody treatment. Treatment 
with  anti-TGF-β antibody  increases  the  infiltration  of  acti-
vated CD8
＋ T cells expressing CD122, cytotoxic effector mol-
ecules such as perforin and granzyme B and Fas ligand in 
metastatic  lesions  (19,20). 
    It is remarkable that CD8
＋ T cells mainly impact the size 
of  tumor  metastasis,  whereas  NK  cells  dramatically  impact 
metastasis number in poorly immunogenic 4T1 mammary tu-
mor metastasis model. CD8
＋ T cells do not significantly affect 
the number of metastasis. Treatment with anti-TGF-β anti-
body restores the cytolytic CD8
＋ T cell activity similar to NK 
cell activity to reduce tumor metastasis number to some ex-
tent,  although  very  highly  activated  NK  cells  are  not  sig-
nificantly affected by anti-TGF-β antibody (19). When TGF-
β antagonists are administered systemically, untoward effects 
by  autoimmune  reactions  might  be  possible  (2).  However, 
anti-TGF-β antibody increases cytotoxic T cell activity only 
locally at the tumor sites without activating systemic immune 
system, which indicates that the clinical application of TGF-β 
antagonists  to  cancer  patients  is  tolerable  (4-6,19,20).
TGF-β AND TUMOR IMMUNE SUBVERSION- 
AFFECTING SIZE OF TUMOR AND METASTASIS
The  balance  between  the  effector  cell  populations  and  the 
suppressor cell populations finely tunes immune system. In 
malignant  tumor  environment,  the  suppressor  populations 
such as Foxp3
＋ Tregs and suppressor myeloid cells dominate Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
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Figure 2. The role of TGF-β in subverting the CD8
+ T cell response. 
TGF-β produced and activated in the tumor environment suppresses 
the immune surveillance, which mainly affects the number of 
metastasis by preventing the generation of cytotoxic T cells. On the 
other hand, TGF-β in combination with other factors, such as IL-6, 
subverts CD8
+ T cells into IL-17 producing cells, which mainly affects 
the size of tumor and metastasis. IL-17 might promote survival of 
tumor cells in the condition with low nutrition or chemotherapy. 
Figure 3. The role of TGF-β in subverting the CD4
+ T cell response. 
TGF-β directly or indirectly suppresses cytotoxic T cells via the 
suppression of CD4
+ Th1 cells. TGF-β, presumably in combination 
with other factors, subverts CD4
+ T cells into Foxp3
+ Tregs or Th17
cells.
over effector cell populations and suppress the effective an-
ti-tumor  immunity.  Large  amount  of  TGF-β produced  and 
activated  in  tumor  environment  promotes  the  development 
and  migration  of  these  suppressor  populations  (21,22).
    Recently,  the  novel  subset  of  CD8
＋  T  cells  is  identified, 
which promotes growth of primary and metastatic tumor (23). 
This CD8
＋ T cell subset is distinct from the reported CD8
＋ 
suppressor/regulatory T cells (24). IL-17 is produced by this 
subset,  which  favors  tumor  growth  by  preventing  tumor 
apoptosis.  The  same  combination  of  cytokines  to  induce 
Th17 CD4
＋ T cells in vitro, TGF-β and IL-6, subverts CD8
＋ 
T  cells  into  this  IL-17  producing  CD8
＋ T  c e l l s  ( F i g .  2 ) .
    The importance of IL-17 in inflammatory autoimmune dis-
orders was first addressed by Nakae S et al. (25) and the CD4
＋ 
T  c e l l  s u b s e t  p r o d u c i n g  I L - 1 7  w a s  d e f i n e d  a s  T h 1 7  b y  
Stockinger B et al. (26). Although T cells infiltrated in tumors 
produce IL-17 (27), it has been controversial whether IL-17 
promotes or inhibits tumor growth (28,29). Recently, it is re-
ported  that  IL-17  produced  by  CD4
＋ T  c e l l s ,  n o t  C D 8
＋ T  
cells, promotes primary tumor growth through IL-6-Stat3 sig-
naling  pathway  (30).
    In  poorly  immunogenic  4T1  metastatic  mammary  tumor 
model, CD8
＋ T cell depletion decreases the primary tumor 
volume as well as metastasis size, indicating that some CD8
＋ 
T cells are not cytotoxic, but on the contrary, favor the tumor 
growth  (23).  IL-17  produced  by  tumor  infiltrating  CD8
＋ T  
cells was identified as the major soluble factor to prevent tu-
mor cell apoptosis, and the knockdown of IL-17 response of 
tumor cells reduces tumor growth by enhancing apoptosis in 
vivo. IL-17 alone or in combination with TGF-β suppresses 
apoptosis  of  tumor  cells  under  the  condition  with  nutrient 
deprivation or the treatment with apoptosis inducer. It might 
not be universal phenomena for all the malignant tumors, be-
cause some tumor cell lines do not respond to IL-17 and in 
some tumors, IL-17 oppositely induces apoptosis. However, 
some patients exhibiting the up-regulation of IL-17 expression 
in  tumor  (23,27)  might  benefit  from  anti-TGF-β treatment 
through  the  same  mechanism. 
    It has been reported that IL-23 is required for autoimmune 
inflammation mediated by Th17 cells in vivo. It is consistent 
with the results of lower numbers of IL-17
＋ T cells in IL-23 
deficient  mice.  These  findings  suggest  that  IL-23-dependent 
signaling in Th-17 cells may depend on the transcription fac-
tor  Stat3  (31).
    Similarly,  it  is  recently  reported  that  Stat3  promotes 
IL-23-mediated  procarcinogenic  immune  response  while  in-
hibiting IL-12-dependent antitumor immunity (32). However, 
it is not yet determined whether IL-23 is required for the de-
velopment of IL-17-producing CD4
＋ T cells and IL-17-produ-
cing CD8
＋ T cells infiltrated in tumor in vivo. They also re-
port  that  Stat3  is  phosphorylated  through  IL-23  receptor  to 
up-regulate the expression of Foxp3 and immunosuppressive 
cytokine, IL-10 in CD4
＋ T cells (Fig. 3). It is also to be de-Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
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termined  whether  TGF-β i s  i n v o l v e d  i n  t h i s  e f f e c t .  T h e  
IL-17/IL-23 axis might be the new mechanism of tumor im-
mune  subversion  (33).
PERSPECTIVE
Researchers used to focus on tumor immune surveillance by 
effector cell populations to enhance tumor immunity. Recent 
accumulation of data shows the importance of regulating tu-
mor immune subversion by suppressor cell populations to re-
verse immune suppression against tumor. Antagonizing TGF-
β successfully enhances tumor immune surveillance and re-
verses immune subversion, which results in the decrease in 
the  number  of  metastasis  and  the  size  of  tumor  and  meta-
stasis. So far, TGF-β antagonists are applied to the treatment 
of terminal stage patients of certain highly malignant cancers 
only in clinical trials. By further confirmation of their efficacy 
and little toxicity, their application might be expanded to the 
patients with general cancers before the radical surgery to de-
crease the size of primary tumors and to prevent metastasis 
or  to the  patients  before  the metastasectomy  to  reduce  the 
s i z e  a n d  t h e  n u m b e r  o f  m e t a s t a s i s .
ACKNOWLEDGEMENTS
We thank Dr. Jeong-Seok Nam, Jin-Ah Park, Ji-Hyun Park and 
the  members  of  the  Laboratory  of  Immunology  for  helpful 
discussions.
CONFLICTS OF INTEREST
The  authors  have  no  financial  conflict  of  interest.
REFERENCES
1. Miyazono K, Kusanagi K, Inoue H: Divergence and con-
vergence  of  TGF-beta/BMP  signaling.  J  Cell  Physiol 
187;265-276,  2001
2. Li  MO,  Wan  YY,  Sanjabi  S,  Robertson  AK,  Flavell  RA: 
Transforming  growth  factor-beta  regulation  of  immune 
responses.  Annu  Rev  Immunol  24;99-146,  2006
3. Roberts AB, Wakefield LM: The two faces of transforming 
growth factor beta in carcinogenesis. Proc Natl Acad Sci U 
S  A  100;8621-8623,  2003
4. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, 
MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver 
MR, Merlino G, Wakefield LM: Lifetime exposure to a solu-
ble  TGF-beta  antagonist  protects  mice  against  metastasis 
without adverse side effects. J Clin Invest 109;1607-1615, 
2002
5 . G e  R , R a je e v  V , R a y  P , L a ttim e  E , R ittlin g  S , M e d ic h e rla 
S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner 
G, Barnard N, Reiss M: Inhibition of growth and metastasis 
of  mouse  mammary  carcinoma  by  selective  inhibitor  of 
transforming growth factor-beta type I receptor kinase  in 
vivo.  Clin  Cancer  Res  12;4315-4330,  2006
6. Wrzesinski SH, Wan YY, Flavell RA: Transforming growth 
factor-beta and the immune response: implications for anti-
cancer  therapy.  Clin  Cancer  Res  13;5262-5270,  2007
7. Denoix PF: Enquete permanent dans les centres anticance-
r e a u x .  B u ll  I n s t N a t H y g  1 ;7 0 - 7 5 , 1 9 4 6
8. Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, 
Miyahara R, Bando T, Okubo K, Hirata T, Toi M, Date H: 
Clinical features of surgical resection for pulmonary meta-
stasis from breast cancer. Eur J Surg Oncol 35;393-397, 2009
9. Humphrey  LJ,  Singla  O,  Volenec  FJ:  Immunologic  re-
sponsiveness of the breast cancer patient. Cancer 46;893- 
898,  1980
10. Ghiringhelli  F,  Puig  PE,  Roux  S,  Parcellier  A,  Schmitt  E, 
Solary  E,  Kroemer  G,  Martin  F,  Chauffert  B,  Zitvogel  L: 
Tumor cells convert immature myeloid dendritic cells into 
TGF-beta-secreting cells inducing CD4+CD25+ regulatory T 
cell proliferation.  J Exp Med 202;919-929, 2005
11. Alleva DG, Burger CJ, Elgert KD: Tumor-induced regulation 
of  suppressor  macrophage  nitric  oxide  and  TNF-alpha 
production.  Role  of  tumor-derived  IL-10,  TGF-beta,  and 
prostaglandin  E2.  J  Immunol  153;1674-1686,  1994
12. Bierie B, Moses HL: Tumour microenvironment: TGFbeta: 
the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 
6;506-520,  2006
13. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related 
inflammation.  Nature  454;436-444,  2008
14. Yang L, Moses HL: Transforming growth factor beta: tumor 
suppressor or promoter? Are host immune cells the answer? 
Cancer  Res  68;9107-9111,  2008
15. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, 
Sporn MB: Transforming growth factor beta 1 (TGF-beta 1) 
controls expression of major histocompatibility genes in the 
postnatal  mouse:  aberrant  histocompatibility  antigen  ex-
pression in the pathogenesis of the TGF-beta 1 null mouse 
phenotype. Proc Natl Acad Sci U S A 90;9944-9948, 1993
16. Ljunggren HG, Kärre K: In search of the ‘missing self: MHC 
molecules  and  NK  cell  recognition.  Immunol  Today  11; 
237-244,  1990
17. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE: 
Cytokine-driven  regulation  of  NK  cell  functions  in  tumor 
immunity:  role  of  the  MICA-NKG2D  system.  Cytokine 
Growth  Factor  Rev  18;159-170,  2007
18. Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 se-
cretion  and  down-modulation  of  NKG2D  underlies  im-
p a i r e d  N K  c y t o t o x i c i t y  i n  c a n c e r  p a t i e n t s .  J  I m m u n o l  
172;7335-7340,  2004
19. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten 
C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, 
Danielpour D, Lonning S, Berzofsky JA, Wakefield LM: An 
anti-transforming  growth  factor  beta  antibody  suppresses 
metastasis via cooperative effects on multiple cell compart-Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
Hae-Young Park, et al.
126 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 4 August 2009
ments.  Cancer  Res  68;3835-3843,  2008
20. Thomas DA, Massagué J: TGF-beta directly targets cytotoxic 
T  cell  functions  during  tumor  evasion  of  immune 
surveillance.  Cancer  Cell  8;369-380,  2005
21. Yamaguchi T, Sakaguchi S: Regulatory T cells in immune 
surveillance  and  treatment  of  cancer.  Semin  Cancer  Biol 
16;115-123,  2006
22. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi 
H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi 
A, Minato N, Taketo MM: SMAD4-deficient intestinal tumors 
recruit  CCR1＋ myeloid  cells  that  promote  invasion.  Nat 
Genet  39;467-475,  2007
23. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, 
L a u r e n c e  A ,  M i c h a l o w s k a  A ,  M a m u r a  M ,  L o n n i n g  S ,  
Berzofsky  JA,  Wakefield  LM:  Transforming  growth  factor 
beta subverts the immune system into directly promoting 
tumor growth through interleukin-17. Cancer Res 68;3915- 
3923,  2008
24. Kapp  JA,  Bucy  RP:  CD8+ suppressor  T  cells resurrected. 
Hum  Immunol  69;715-720,  2008
25. Nakae  S,  Komiyama  Y,  Nambu  A,  Sudo  K,  Iwase  M, 
Homma I, Sekikawa K, Asano M, Iwakura Y: Antigen-spe-
cific T cell sensitization is impaired in IL-17-deficient mice, 
causing  suppression  of  allergic  cellular  and  humoral 
responses.  Immunity  17;375-387,  2002
26. Veldhoen  M,  Hocking  RJ,  Atkins  CJ,  Locksley  RM, 
Stockinger B: TGF beta in the context of an inflammatory 
cytokine  milieu  supports  de  novo  differentiation  of 
IL-17-producing  T  cells.  Immunity  24;179-189,  2006
27. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang 
RF: Generation and regulation of human CD4＋ IL-17- pro-
ducing T cells in ovarian cancer. Proc Natl Acad Sci U S 
A  105;15505-15510,  2008
28. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, 
Kudo T, Robbins PD, Tahara H, Lotze MT: Interleukin-17 
promotes angiogenesis and tumor growth. Blood 101;2620- 
2627,  2003
29. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W: Endogenous 
IL-17 contributes to reduced tumor growth and metastasis. 
Blood  114;357-359,  2009
30. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: 
IL-17 can promote tumor growth through an IL-6-Stat3 sig-
naling  pathway.  J  Exp  Med  206;1457-1464,  2009
31. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh 
B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ: 
The interleukin 23 receptor is essential for the terminal dif-
ferentiation  of  interleukin  17-producing  effector  T  helper 
cells in vivo.  Nat  Immunol  10;314-324,  2009
32. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris 
T, Drake C, Pardoll D, Yu H: Regulation of the IL-23 and 
IL-12  balance  by  Stat3  signaling  in  the  tumor  microen-
vironment.  Cancer  Cell  15;114-123,  2009
33. Martin-Orozco  N,  Dong  C:  The  IL-17/IL-23  axis  of  in-
flammation  in  cancer:  friend  or  foe?  Curr  Opin  Investig 
Drugs  10;543-549,  2009